Yarrow Bioscience Inc (YARW) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Yarrow Bioscience Inc (YARW) has a cash flow conversion efficiency ratio of -0.166x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.08 Million) by net assets ($24.64 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Review Yarrow Bioscience Inc leverage flexibility ratio to assess the company's free cash flow relative to its total liabilities.
Yarrow Bioscience Inc - Cash Flow Conversion Efficiency Trend (2015–2025)
This chart illustrates how Yarrow Bioscience Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Also see Yarrow Bioscience Inc market cap and net worth for the company's overall valuation and market capitalisation.
Yarrow Bioscience Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Yarrow Bioscience Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Platform Turizm Tasimacilik AS
IS:PLTUR
|
0.145x |
|
QRF SCA
BR:QRF
|
-0.001x |
|
Caravel Minerals Ltd
AU:CVV
|
-0.375x |
|
Noroo Paint
KO:090350
|
-0.029x |
|
Softstar Entertainment
TWO:6111
|
-0.024x |
|
Grange Resources Ltd
AU:GRR
|
0.038x |
|
Bokusgruppen AB
ST:BOKUS
|
-0.040x |
|
Intema Insaat ve Tesisat Malzemeleri Yatirim ve Pazarlama AS
IS:INTEM
|
-0.034x |
Annual Cash Flow Conversion Efficiency for Yarrow Bioscience Inc (2015–2025)
The table below shows the annual cash flow conversion efficiency of Yarrow Bioscience Inc from 2015 to 2025. View today's stock price for Yarrow Bioscience Inc for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $27.77 Million | $-33.12 Million | -1.193x | -82.91% |
| 2024-12-31 | $52.09 Million | $-33.97 Million | -0.652x | -128.39% |
| 2023-12-31 | $88.73 Million | $-25.34 Million | -0.286x | +69.48% |
| 2022-12-31 | $31.20 Million | $-29.20 Million | -0.936x | +19.25% |
| 2021-12-31 | $48.64 Million | $-56.37 Million | -1.159x | +68.30% |
| 2020-12-31 | $37.49 Million | $-137.08 Million | -3.656x | -284.75% |
| 2019-12-31 | $68.51 Million | $-65.10 Million | -0.950x | -134.94% |
| 2018-12-31 | $130.38 Million | $-52.73 Million | -0.404x | -181.67% |
| 2017-12-31 | $-57.03 Million | $-28.25 Million | 0.495x | +536.45% |
| 2016-12-31 | $-29.44 Million | $-2.29 Million | 0.078x | -70.32% |
| 2015-12-31 | $-15.95 Million | $-4.18 Million | 0.262x | -- |
About Yarrow Bioscience Inc
Yarrow Bioscience, Inc. operates as a clinical-stage biotechnology company that engages in developing transformative therapies for autoimmune thyroid diseases. The company's candidate, YB-101, is a humanized monoclonal antibody targeting the thyroid-stimulating hormone receptor (TSHR) for the treatment of Graves' disease and thyroid eye disease. The company was incorporated in 2025 and is based i… Read more